<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02432365</url>
  </required_header>
  <id_info>
    <org_study_id>AGOG14-001/TGOG1008</org_study_id>
    <secondary_id>IRB103-4781A3</secondary_id>
    <nct_id>NCT02432365</nct_id>
  </id_info>
  <brief_title>Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy</brief_title>
  <official_title>Phase II Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Asian Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taiwanese Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose was to establish a quick (7-day) cycle schedule of paclitaxel (60 mg/m2)&#xD;
      combining with cisplatin (40 mg/m2) NAC regimen could be tolerated without interfering the&#xD;
      following surgical treatment and a favorable overall survival rate for stages IB2 and IIA2&#xD;
      cervical squamous cell carcinoma (SCC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, open-label, Simon's 2-stage, phase II study of paclitaxel and&#xD;
      cisplatin as neoadjuvant therapy in patients with FIGO IB2 or IIA2, squamous cell cervical&#xD;
      carcinoma of the uterine cervix.&#xD;
&#xD;
      Primary Objectives:&#xD;
&#xD;
      • Overall survival&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  Safety&#xD;
&#xD;
        -  Progression-free survival&#xD;
&#xD;
        -  Response rate&#xD;
&#xD;
        -  Postoperative RT/CRT rate&#xD;
&#xD;
        -  To assess Quality-of-life&#xD;
&#xD;
      An estimate of 64 evaluable patients will be enrolled in this phase II investigation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survivial</measure>
    <time_frame>January 31, 2023 (5 years)</time_frame>
    <description>The primary objective is to determinate the difference in 5-year survival rate of subjects with NAC+RH-PLND compared with standard CCRT. Based on the pilot research, the 5-year survival rate of NAC+RH-PLND is expected to be around 87.5%. Thus, a sample size of 64 subjects in NAC+RH-PLND group is required for correctly detecting a 12.5% difference between 5-year OS rate of NAC+RH-PLND group and a reference value 75% of standard CCRT in order to achieving an 80% power at a significance level 0.05.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (If &gt; 6 significant G3/4 AEs occur)</measure>
    <time_frame>January 31, 2023 (up to 5 years)</time_frame>
    <description>If &gt; 6 significant G3/4 AEs occur</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate (Pathological response)</measure>
    <time_frame>Post-operative 1 month</time_frame>
    <description>Pathological response will be calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postoperative RT/CRT rate</measure>
    <time_frame>Post-operative 6 months</time_frame>
    <description>Postoperative RT/CCRT will be given to defined high-risk group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-life</measure>
    <time_frame>at completion of neoadjuvant chemotherapy</time_frame>
    <description>using EORTC QLQ-C30, EORTC-QLQ-CX24</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>January 31, 2023 (up to 5 years)</time_frame>
    <description>PFS will be evaluated using Kaplan-Meier method</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Weekly paclitaxel and cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7-day cycle schedule of paclitaxel (60 mg/m2) combining with cisplatin (40 mg/m2) NAC regimen followed by radical hysterectomy and bilateral pelvic lymphadenectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
    <description>7-day cycle schedule of paclitaxel (60 mg/m2)</description>
    <arm_group_label>Weekly paclitaxel and cisplatin</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>7-day cycle schedule of cisplatin (40 mg/m2)</description>
    <arm_group_label>Weekly paclitaxel and cisplatin</arm_group_label>
    <other_name>Kemoplat</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical hysterectomy and bilateral pelvic lymphadenectomy</intervention_name>
    <description>2 weeks after last course of neoadjuvant chemotherapy</description>
    <arm_group_label>Weekly paclitaxel and cisplatin</arm_group_label>
    <other_name>RH-PLND</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women with previously untreated, histologically confirmed squamous cell carcinoma of&#xD;
             the uterine cervix&#xD;
&#xD;
          2. HPV16-positive aged 35-70 years or HPV16-negative age &lt;55 years&#xD;
&#xD;
          3. FIGO stage IB2 or bulky IIA, with tumor extending to the vagina within the upper one&#xD;
             third of the vaginal wall. Bulky tumor is defined as&#xD;
&#xD;
               1. a visible cervical tumor with the largest diameter &gt;4 cm or (b) a cervix expanded&#xD;
                  to &gt; 4 cm as a result of tumor infiltration by pelvic examination&#xD;
&#xD;
               2. verified by magnetic resonance image (MRI) or 3-dimensional (D) computed&#xD;
                  tomography (CT)&#xD;
&#xD;
          4. no suspicious extrapelvic metastasis detected by MRI or 3-D CT&#xD;
&#xD;
          5. adequate marrow, liver and renal functions :hemoglobin level &gt;= 10 g/dL, WBC count &gt;=&#xD;
             3,000/mm3 or absolute neutrophil count &gt;= 1,500/mm3, platelet count &gt;= 100,000/mm3,&#xD;
             serum transaminase (AST, ALT) levels &lt;= 60 IU/mL, total serum bilirubin within normal&#xD;
             range, serum creatinine level &lt;= 1.5 mg/dL, and blood urea nitrogen level &lt;=20 mg/dL&#xD;
&#xD;
          6. adequate cardiopulmonary function that tolerates the administration of study regimen&#xD;
             and radical hysterectomy&#xD;
&#xD;
          7. Eastern Cooperative Oncology Group performance status of 0 to 1&#xD;
&#xD;
          8. had written informed consent to participate in the study&#xD;
&#xD;
          9. Appropriate organ and marrow function :&#xD;
&#xD;
             leukocytes &gt;=3,000/μL absolute neutrophil count &gt;= 1,500/μL platelets &gt;= 100,000/μL&#xD;
             (not platelet transfusion dependent) hemoglobin &gt;= 10 g/dL total bilirubin within&#xD;
             normal range AST/ALT &lt;= 2.5 X upper limit of normal range (ULN) BUN &lt;= 20 mg/dL serum&#xD;
             creatinine &lt;=1.5 mg/dL or clearance &gt; 60 mL/min&#xD;
&#xD;
         10. a negative urinary pregnancy test in a patient with child-bearing potential&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Patients will be excluded from the study if they meet any of the following criteria:&#xD;
&#xD;
          1. adenocarcinoma , adenosquamous carcinoma, or small cell carcinoma&#xD;
&#xD;
          2. concurrent or history of malignant tumor(s) other than treated nonmelanoma skin cancer&#xD;
&#xD;
          3. had received surgical procedure other than cervical biopsy or cytotoxic procedure&#xD;
             including chemotherapy, radiotherapy or therapy with biologic response modifier(s) for&#xD;
             the cervical tumor&#xD;
&#xD;
          4. enlarged pelvic lymph node with positive aspiration cytologic or histologic study&#xD;
&#xD;
          5. participate in investigational treatment or another clinical trial for cervical cancer&#xD;
&#xD;
          6. history of allergic reaction to platinum or paclitaxel&#xD;
&#xD;
          7. uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          8. pregnant or breast feeding women&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huei-Jean Huang, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic oncology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huei-Jean Huang, M.D</last_name>
    <phone>03-3281200</phone>
    <phone_ext>8984</phone_ext>
    <email>hjhuang@cgmh.org.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Obstetrics &amp; Gynecology, Chang Gung Memorial Hospital</name>
      <address>
        <city>Chiayi City</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chih-Wen Tseng, M.D.</last_name>
      <email>otcwwell@cgmh.org.tw</email>
    </contact>
    <investigator>
      <last_name>Chih-Wen Tseng, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Obstetrics &amp; Gynecology, Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hung-Chun Fu, M.D.</last_name>
      <phone>886-7-731-7123</phone>
      <phone_ext>8916</phone_ext>
      <email>allen133@adm.cgmh.org.tw</email>
    </contact>
    <investigator>
      <last_name>Hong-Jun Fu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, Chung Shan Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chih-Jen Tseng, M.D.</last_name>
      <phone>886-4-24739595</phone>
      <phone_ext>34121</phone_ext>
      <email>obgyntw@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chih-Jen Tseng, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Obstetrics &amp; Gynecology, Chang Gung Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jui-Der Liou, M.D.</last_name>
      <phone>886-2-27135211</phone>
      <phone_ext>3345</phone_ext>
      <email>liou88@ms13.hinet.net</email>
    </contact>
    <investigator>
      <last_name>Jui-Der Liou, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Gynecologic Oncology, Department of Obstetrics &amp; Gynecology, Chang Gung Memorial Hospital Linkou Medical Center</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huei-Jean Huang, M.D.</last_name>
      <email>hueijean.huang@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Huei-Jean Huang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <link>
    <url>https://medlineplus.gov/hysterectomy.html</url>
    <description>MedlinePlus related topics</description>
  </link>
  <link>
    <url>https://druginfo.nlm.nih.gov/drugportal/name/Paclitaxel</url>
    <description>Drug Information available for: Paclitaxel</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>U.S. FDA Resources</description>
  </link>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>May 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2015</study_first_posted>
  <last_update_submitted>October 27, 2017</last_update_submitted>
  <last_update_submitted_qc>October 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Huei-Jean Huang</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Paclitaxel</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Cervical cancer</keyword>
  <keyword>Radical hysterectomy</keyword>
  <keyword>Neoadjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

